Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aravive, Inc. stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
$2.46
$2.95M2.19N/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
$0.05
$0.03
$0.54
$11.47M-0.26360,154 shs25,935 shs
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$0.40
-0.8%
$0.48
$0.35
$4.90
$11.33M1.21883,890 shs203,390 shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$0.25
-2.8%
$0.28
$0.22
$3.42
$11.33M0.481.15 million shs689,420 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aravive, Inc. stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Bright Green Co. stock logo
BGXX
Bright Green
0.00%0.00%0.00%+50.00%-70.54%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-0.80%-1.78%-17.38%-52.23%+39,799,900.00%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-2.81%-1.29%-17.07%-14.50%-91.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aravive, Inc. stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
1.4746 of 5 stars
3.50.00.00.00.01.70.6
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
1.3424 of 5 stars
3.22.00.00.01.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aravive, Inc. stock logo
ARAV
Aravive
0.00
N/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
0.00
N/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3.00
Buy$10.002,412.56% Upside
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.33
Hold$12.504,985.44% Upside

Current Analyst Ratings Breakdown

Latest ARAV, CLDI, CLRB, and BGXX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aravive, Inc. stock logo
ARAV
Aravive
$6.99M0.42N/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/A$0.06 per shareN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$50K226.61N/AN/A($2.32) per share-0.17
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A($0.96) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aravive, Inc. stock logo
ARAV
Aravive
-$76.32MN/A0.00N/AN/AN/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)

Latest ARAV, CLDI, CLRB, and BGXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$0.17-$0.13+$0.04-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aravive, Inc. stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aravive, Inc. stock logo
ARAV
Aravive
N/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
N/A
0.01
0.01
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
1.77
1.77

Institutional Ownership

CompanyInstitutional Ownership
Aravive, Inc. stock logo
ARAV
Aravive
35.80%
Bright Green Co. stock logo
BGXX
Bright Green
7.83%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%

Insider Ownership

CompanyInsider Ownership
Aravive, Inc. stock logo
ARAV
Aravive
60.40%
Bright Green Co. stock logo
BGXX
Bright Green
62.55%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
24.28%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aravive, Inc. stock logo
ARAV
Aravive
2073.56 million29.13 millionNo Data
Bright Green Co. stock logo
BGXX
Bright Green
2191.17 million71.59 millionNo Data
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3828.47 million20.04 millionN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
1046.08 million44.38 millionOptionable

Recent News About These Companies

Oppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)
Q4 2024 Cellectar Biosciences Inc Earnings Call
Cellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 05/27/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Bright Green stock logo

Bright Green NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$0.40 0.00 (-0.80%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.40 +0.00 (+0.25%)
As of 05/28/2025 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$0.25 -0.01 (-2.81%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.24 0.00 (-1.95%)
As of 05/28/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.